SCHEDULE 13G/A: Viking Global Investors Maintains Significant 9.2% Stake in Oric Pharmaceuticals

Viking Global Investors LP and its affiliated entities have filed an amended Schedule 13G, reaffirming their beneficial ownership of 9.2% of Oric Pharmaceuticals, Inc.'s common stock.

Summary

• Viking Global Investors LP (VGI) and its related entities, including Viking Global Opportunities Parent GP LLC, Viking Global Opportunities GP LLC, Viking Global Opportunities Portfolio GP LLC, Viking Global Opportunities Illiquid Investments Sub-Master LP (VGOP), Viking Global Opportunities Drawdown GP LLC (VGOD GP), Viking Global Opportunities Drawdown Portfolio GP LLC (VGOD Portfolio GP), and Viking Global Opportunities Drawdown (Aggregator) LP (VGOD), collectively beneficially own 6,572,700 shares of Oric Pharmaceuticals, Inc. common stock.
• This aggregate ownership represents 9.2% of Oric Pharmaceuticals' outstanding common stock, based on 71,078,511 shares reported as outstanding as of March 31, 2025.
• The beneficial ownership is primarily held through VGOP (4,312,800 shares) and VGOD (2,259,900 shares).
• O. Andreas Halvorsen, David C. Ott, and Rose S. Shabet, as Executive Committee Members of Viking Global Partners LLC and Opportunities Parent, share voting and dispositive power over the 6,572,700 shares.
• The filing states that the securities were not acquired and are not held for the purpose of changing or influencing the control of Oric Pharmaceuticals, other than activities solely in connection with a nomination under Rule 14a-11.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing disclosing beneficial ownership. It is neutral in tone and content, providing factual information without expressing positive or negative sentiment about the company's performance or prospects.

Positives

• The continued significant stake by a prominent institutional investor like Viking Global Investors may signal ongoing confidence in Oric Pharmaceuticals' long-term prospects.
• The passive nature of the investment, as indicated by the Schedule 13G filing, suggests that Viking Global is not seeking to influence or change control of the issuer, which can provide stability.

Risks

• The filing indicates a passive investment strategy, meaning Viking Global Investors is not actively seeking to influence the management or strategic direction of Oric Pharmaceuticals, which could limit their direct impact on company performance.

Future Outlook

This Schedule 13G filing is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance regarding Oric Pharmaceuticals' future performance or strategic outlook.

Industry Context

This filing reflects a significant institutional investment in a biotechnology/pharmaceutical company, a common practice where investment firms take substantial, often passive, stakes in companies within sectors they believe have growth potential. The specific impact on broader industry trends is not detailed in this ownership disclosure.

Stakeholder Impact

• Shareholders: The continued significant ownership by Viking Global Investors may be viewed positively, indicating a large institutional investor's sustained interest and confidence in Oric Pharmaceuticals.

Key Dates

Keywords

Oric Pharmaceuticals, Viking Global Investors, Schedule 13G, Beneficial Ownership, Institutional Investment, Common Stock, Biotechnology, Pharmaceuticals, SEC Filing